Population pharmacokinetics of oseltamivir in non‐pregnant and pregnant women
Open Access
- 3 June 2015
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 80 (5) , 1042-1050
Abstract
Aims: Physiological changes in pregnancy are expected to alter the pharmacokinetics of various drugs. The objective of this study was to evaluate systematically the pharmacokinetics of oseltamivir (OS), a drug used in the treatment of influenza during pregnancy.Methods: A multicentre steady‐state pharmacokinetic study of OS was performed in 35 non‐pregnant and 29 pregnant women. Plasma concentration–time profiles were analyzed using both non‐compartmental and population pharmacokinetic modelling (pop PK) and simulation approaches. A one compartment population pharmacokinetic model with first order absorption and elimination adequately described the pharmacokinetics of OS.Results: The systemic exposure of oseltamivir carboxylate (OC, active metabolite of OS) was reduced approximately 30 (19–36)% (P < 0.001) in pregnant women. Pregnancy significantly (P < 0.001) influenced the clearance (CL/F) and volume of distribution (V/F) of OC. Both non‐compartmental and population pharmacokinetic approaches documented approximately 45 (23–62)% increase in clearance (CL/F) of OC during pregnancy.Conclusion: Based on the decrease in exposure of the active metabolite, the currently recommended doses of OS may need to be increased modestly in pregnant women in order to achieve comparable exposure with that of non‐pregnant women.Keywords
Funding Information
- National Institute of Child Health and Human Development (5U10 HD 047905)
- National Institute of Child Health and Human Development (U10 HD047892)
- National Institute of Child Health and Human Development (3U10 HD047891-05S2)
This publication has 25 references indexed in Scilit:
- Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation StudiesAntimicrobial Agents and Chemotherapy, 2013
- Population Pharmacokinetics of Oseltamivir: Pediatrics through GeriatricsAntimicrobial Agents and Chemotherapy, 2013
- 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literatureAmerican Journal of Obstetrics and Gynecology, 2011
- Pharmacokinetics of oseltamivir according to trimester of pregnancyAmerican Journal of Obstetrics and Gynecology, 2011
- Maternal deaths associated with H1N1 influenza virus infection in Turkey: a whole-of-population reportBJOG: An International Journal of Obstetrics & Gynaecology, 2011
- Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).2011
- Viral Infection of the Placenta Leads to Fetal Inflammation and Sensitization to Bacterial Products Predisposing to Preterm LaborThe Journal of Immunology, 2010
- Development of a high-performance liquid chromatographic–mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- Pharmacokinetic Changes During Pregnancy and Their Clinical RelevanceClinical Pharmacokinetics, 1997
- Renal hemodynamics and tubular function in normal human pregnancyKidney International, 1980